PRA Health Sciences, Inc. (NASDAQ:PRAH) – Analysts at William Blair lifted their Q4 2017 EPS estimates for PRA Health Sciences in a research note issued to investors on Wednesday. William Blair analyst J. Kreger now anticipates that the medical research company will post earnings per share of $1.00 for the quarter, up from their previous forecast of $0.91.

A number of other analysts have also commented on the company. SunTrust Banks, Inc. reissued a “buy” rating and set a $94.00 price objective on shares of PRA Health Sciences in a report on Friday. Credit Suisse Group boosted their price objective on PRA Health Sciences from $90.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday. Jefferies Group LLC reissued a “buy” rating and set a $95.00 price objective on shares of PRA Health Sciences in a report on Thursday. Robert W. Baird reissued a “buy” rating and set a $88.00 price objective on shares of PRA Health Sciences in a report on Monday, October 9th. Finally, Mizuho began coverage on PRA Health Sciences in a report on Thursday, September 21st. They set a “buy” rating and a $82.00 price objective for the company. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. PRA Health Sciences presently has a consensus rating of “Buy” and an average price target of $86.90.

WARNING: “Analysts Set Expectations for PRA Health Sciences, Inc.’s Q4 2017 Earnings (PRAH)” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/30/analysts-set-expectations-for-pra-health-sciences-inc-s-q4-2017-earnings-prah.html.

PRA Health Sciences (NASDAQ:PRAH) opened at 82.04 on Monday. The company’s 50-day moving average price is $78.54 and its 200 day moving average price is $74.02. The firm has a market capitalization of $5.14 billion, a PE ratio of 52.96 and a beta of 0.42. PRA Health Sciences has a 12 month low of $50.87 and a 12 month high of $84.38.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.03. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The company had revenue of $494.55 million during the quarter, compared to analysts’ expectations of $477.89 million. During the same period in the prior year, the firm earned $0.64 earnings per share. PRA Health Sciences’s revenue for the quarter was up 23.7% compared to the same quarter last year.

In other news, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $711,075,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Colin Shannon sold 400,000 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $29,940,000.00. The disclosure for this sale can be found here. Insiders sold a total of 10,000,000 shares of company stock worth $748,500,000 in the last 90 days. Company insiders own 2.10% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in PRAH. BlackRock Inc. boosted its stake in shares of PRA Health Sciences by 43,947.8% in the 1st quarter. BlackRock Inc. now owns 2,857,381 shares of the medical research company’s stock worth $186,387,000 after buying an additional 2,850,894 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of PRA Health Sciences by 318.3% in the 2nd quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock worth $163,172,000 after buying an additional 1,655,336 shares during the last quarter. Harbour Capital Advisors LLC purchased a new position in shares of PRA Health Sciences in the 2nd quarter worth approximately $6,400,000. Renaissance Technologies LLC purchased a new position in shares of PRA Health Sciences in the 1st quarter worth approximately $20,339,000. Finally, Hood River Capital Management LLC boosted its stake in shares of PRA Health Sciences by 80.3% in the 2nd quarter. Hood River Capital Management LLC now owns 619,924 shares of the medical research company’s stock worth $46,500,000 after buying an additional 276,045 shares during the last quarter. Hedge funds and other institutional investors own 98.48% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.